Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Effect of Lidocaine/Dexamethasone on the Success of IANB

Phase 2

Completed

Conditions: Local Anesthesia

Interventions: Drug: Dexamethasone
Drug: Placebo

First Posted Date: 2018-05-22

Last Posted Date: 2018-05-22

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT03531970

Locations: 🇮🇷
Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Lymphoma
Multiple Myeloma
Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma

Interventions: Drug: Maplirpacept (PF-07901801)
Drug: Anti-CD20 Targeting agent
Drug: Azacitidine
Drug: Carfilzomib
Drug: Venetoclax
Drug: Dexamethasone
Drug: Isatuximab

First Posted Date: 2018-05-21

Last Posted Date: 2023-12-22

Lead Sponsor: Pfizer

Target Recruit Count: 177

Registration Number: NCT03530683

Locations: 🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northside Hospital, Atlanta, Georgia, United States

and more 58 locations

Block Duration After Spinal Block and iv Dexamethasone.

Phase 4

Completed

Conditions: Postoperative Pain
Lower Limb Injury

Interventions: Drug: NaCl 0.0308 MEQ/ML Injectable Solution
Drug: Dexamethasone

First Posted Date: 2018-05-17

Last Posted Date: 2022-07-20

Lead Sponsor: Eric Albrecht

Target Recruit Count: 50

Registration Number: NCT03527576

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Vaud, Switzerland

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Refractory Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2018-05-11

Last Posted Date: 2021-06-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 34

Registration Number: NCT03520985

Locations: 🇨🇭
Onkozentrum Hirslanden Zürich, Zurich, Switzerland
🇨🇭
OnkoZentrum Zürich AG - Klinik im Park, Zürich, Switzerland
🇨🇭
Kantonspital Aarau, Aarau, Switzerland

and more 13 locations